Organ-on-a-Chip Resources

PhysioMimix® cross-species DILI CRS for enhanced IVIVE

Gain clarity, confidence, speed, and enhance your ethical responsibility by leveraging our cross-species Drug-induced liver injury assays (human, rat and dog) in your drug discovery or development workflow. Improve your in vitro to in vivo extrapolation (IVIVE) capabilities today via our DILI Contract Research Service.

CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI

Building Confidence in MPS for Regulatory Applications!

PhysioMimix DILI assay kit: Human 24 brochure

Predict more complex, latent and immune-related hepatotoxicity in vitro. The PhysioMimix DILI assay kit contains everything you need to recreate our FDA-recognized assay in your own laboratory.

Harnessing Liver-on-a-chip models for drug safety

Webinar Series 8 Episode 2

Discover how to leverage human and animal Liver-on-a-chip (aka Liver microphysiological systems) in toxicology studies to enhance data translatability between preclinical testing and clinical applications.

Featuring industry experts from CN Bio and Bristol Myers Squibb.

How OOC can improve in vitro to in vivo translatability of preclinical data

PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights

Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

A human liver microphysiological system for assessing mechanisms of toxicity during drug development

Understand the advantages of using OOC to derive human translatable mechanistic insights ahead of more costly drug development phases.

How Organ-on-a-chip can reduce DILI risk in drug development

Drug-induced Liver injury is a common cause of drug withdrawal during late drug development as well as post-approval. The liver, a primary site of drug metabolism, is particularly susceptible. However, DILI can occur through several pathways, each involving different mechanisms.

This article explores why traditional in vitro and in vivo animal studies are less able to predict more complex indirect or idiosyncratic effects that are latent in onset and how preclinical workflows can be modernized to reduce risk through Organ-on-a-chip’s mechanistic insights.

Evaluating a human DILI assay kit’s ability to unlock complex mechanisms of toxicity

Here, we demonstrate how the PhysioMimix DILI assay kit: Human 24 and PhysioMimix OOC Single-organ System captures more complex mechanisms of human DILI than traditional preclinical approaches to reduce the risk of unforeseen event detection in the clinic.

Scrip Asks… What Does 2025 Hold For Biopharma?

Part 6: Therapeutic Area Advances

In part 6 of this Scrip Asks series, Dr. Tomasz Kostrzewski, joins 40 other biopharma leaders, who share their views on the upcoming developments in key therapeutic areas to look out for. They also discuss multiple scientific fields that are opening up new avenues for treatment.

Go/No-Go

Webinar Series 7 Episode 3

In this webinar “Go/No-Go” we demonstrate how to further de-risk development workflows with the PhysioMimix^® DILI assay. Using drugs that were identified as toxic in the clinic, we reveal some of the data-rich investigative toxicology studies that can be achieved using a human liver microphysiological system (MPS), otherwise known as organ-on-a-chip (OOC).